| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography, Three-Dimensional | 54 | 2024 | 523 | 10.680 |
Why?
|
| Echocardiography | 62 | 2025 | 968 | 7.820 |
Why?
|
| Heart Ventricles | 51 | 2024 | 795 | 7.130 |
Why?
|
| Tricuspid Valve Insufficiency | 19 | 2024 | 123 | 5.540 |
Why?
|
| Ventricular Function, Right | 23 | 2024 | 152 | 4.240 |
Why?
|
| Ventricular Function, Left | 33 | 2024 | 638 | 4.100 |
Why?
|
| Tricuspid Valve | 16 | 2024 | 107 | 3.490 |
Why?
|
| Ventricular Dysfunction, Right | 11 | 2025 | 151 | 2.680 |
Why?
|
| Amyloidosis | 13 | 2024 | 129 | 2.300 |
Why?
|
| Heart Atria | 13 | 2022 | 289 | 2.190 |
Why?
|
| Cardiomyopathies | 8 | 2024 | 272 | 2.150 |
Why?
|
| Ventricular Dysfunction, Left | 12 | 2024 | 335 | 2.130 |
Why?
|
| Stroke Volume | 26 | 2024 | 499 | 2.060 |
Why?
|
| Ventricular Remodeling | 8 | 2024 | 109 | 1.870 |
Why?
|
| Atrial Function, Left | 8 | 2021 | 53 | 1.810 |
Why?
|
| Hypertension, Pulmonary | 7 | 2025 | 376 | 1.740 |
Why?
|
| Heart Failure | 11 | 2023 | 1346 | 1.740 |
Why?
|
| Defibrillators, Implantable | 7 | 2024 | 148 | 1.730 |
Why?
|
| Mitral Valve Insufficiency | 6 | 2024 | 205 | 1.620 |
Why?
|
| Echocardiography, Transesophageal | 12 | 2022 | 358 | 1.580 |
Why?
|
| Predictive Value of Tests | 30 | 2024 | 1763 | 1.540 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 4 | 2024 | 24 | 1.500 |
Why?
|
| Reproducibility of Results | 38 | 2024 | 2794 | 1.450 |
Why?
|
| Humans | 140 | 2025 | 92337 | 1.380 |
Why?
|
| Image Interpretation, Computer-Assisted | 16 | 2024 | 693 | 1.360 |
Why?
|
| Reference Values | 20 | 2024 | 660 | 1.340 |
Why?
|
| Cardiac Volume | 4 | 2017 | 53 | 1.280 |
Why?
|
| Male | 92 | 2024 | 43925 | 1.230 |
Why?
|
| Magnetic Resonance Imaging, Cine | 11 | 2023 | 165 | 1.220 |
Why?
|
| Middle Aged | 68 | 2024 | 27030 | 1.210 |
Why?
|
| Hemodynamics | 6 | 2019 | 756 | 1.190 |
Why?
|
| Female | 92 | 2024 | 47893 | 1.150 |
Why?
|
| Echocardiography, Doppler | 9 | 2020 | 193 | 1.140 |
Why?
|
| Pacemaker, Artificial | 5 | 2024 | 97 | 1.110 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 377 | 1.050 |
Why?
|
| Diastole | 10 | 2021 | 146 | 1.020 |
Why?
|
| Aged | 51 | 2024 | 19943 | 1.020 |
Why?
|
| Heart Diseases | 8 | 2021 | 308 | 1.010 |
Why?
|
| Heart-Assist Devices | 6 | 2021 | 866 | 0.970 |
Why?
|
| Pulmonary Embolism | 3 | 2023 | 230 | 0.910 |
Why?
|
| Thrombophilia | 1 | 2023 | 22 | 0.860 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2023 | 10 | 0.830 |
Why?
|
| Echocardiography, Doppler, Color | 7 | 2022 | 106 | 0.810 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2018 | 1271 | 0.810 |
Why?
|
| Healthy Volunteers | 8 | 2022 | 147 | 0.790 |
Why?
|
| Atrial Remodeling | 2 | 2022 | 24 | 0.790 |
Why?
|
| Myocardial Contraction | 3 | 2018 | 252 | 0.790 |
Why?
|
| Heart | 7 | 2023 | 584 | 0.780 |
Why?
|
| Adult | 45 | 2025 | 27532 | 0.770 |
Why?
|
| Atrial Function, Right | 4 | 2020 | 13 | 0.730 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2020 | 25 | 0.730 |
Why?
|
| Thrombosis | 1 | 2023 | 312 | 0.700 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2020 | 492 | 0.700 |
Why?
|
| Heart Defects, Congenital | 2 | 2014 | 369 | 0.690 |
Why?
|
| Aorta, Thoracic | 2 | 2019 | 167 | 0.680 |
Why?
|
| Observer Variation | 9 | 2024 | 612 | 0.670 |
Why?
|
| Aortic Valve | 5 | 2023 | 260 | 0.620 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 157 | 0.610 |
Why?
|
| Contrast Media | 5 | 2023 | 1076 | 0.600 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 162 | 0.590 |
Why?
|
| Trastuzumab | 2 | 2016 | 78 | 0.590 |
Why?
|
| Hemothorax | 1 | 2018 | 15 | 0.590 |
Why?
|
| Heart Massage | 1 | 2018 | 12 | 0.590 |
Why?
|
| Vascular Calcification | 1 | 2019 | 51 | 0.580 |
Why?
|
| Aortic Diseases | 1 | 2019 | 102 | 0.580 |
Why?
|
| Mitral Valve | 7 | 2022 | 275 | 0.570 |
Why?
|
| Ventricular Fibrillation | 1 | 2018 | 69 | 0.570 |
Why?
|
| Early Diagnosis | 1 | 2018 | 129 | 0.560 |
Why?
|
| Retrospective Studies | 25 | 2024 | 9703 | 0.550 |
Why?
|
| Sensitivity and Specificity | 13 | 2024 | 2009 | 0.540 |
Why?
|
| Aged, 80 and over | 18 | 2024 | 6916 | 0.540 |
Why?
|
| Severity of Illness Index | 14 | 2024 | 1919 | 0.540 |
Why?
|
| Atherosclerosis | 2 | 2024 | 262 | 0.530 |
Why?
|
| Prospective Studies | 20 | 2021 | 4468 | 0.520 |
Why?
|
| Holography | 1 | 2016 | 5 | 0.520 |
Why?
|
| Prognosis | 14 | 2024 | 3872 | 0.520 |
Why?
|
| Anticoagulants | 2 | 2018 | 443 | 0.480 |
Why?
|
| Anthracyclines | 1 | 2015 | 35 | 0.470 |
Why?
|
| Pulmonary Valve | 1 | 2015 | 33 | 0.470 |
Why?
|
| Taxoids | 1 | 2015 | 126 | 0.460 |
Why?
|
| Sex Factors | 5 | 2018 | 1095 | 0.460 |
Why?
|
| Heart Arrest | 1 | 2018 | 283 | 0.450 |
Why?
|
| Echocardiography, Doppler, Pulsed | 3 | 2019 | 24 | 0.450 |
Why?
|
| Algorithms | 6 | 2024 | 1956 | 0.450 |
Why?
|
| Electrodes, Implanted | 2 | 2014 | 197 | 0.440 |
Why?
|
| Veins | 1 | 2014 | 96 | 0.440 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2013 | 23 | 0.430 |
Why?
|
| Mitral Valve Prolapse | 1 | 2013 | 24 | 0.430 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 142 | 0.430 |
Why?
|
| Sample Size | 1 | 2013 | 126 | 0.420 |
Why?
|
| Cardiac Catheterization | 4 | 2019 | 324 | 0.420 |
Why?
|
| Image Enhancement | 8 | 2019 | 562 | 0.410 |
Why?
|
| Decision Making | 1 | 2018 | 680 | 0.410 |
Why?
|
| Machine Learning | 3 | 2020 | 298 | 0.400 |
Why?
|
| Ventricular Pressure | 3 | 2018 | 44 | 0.390 |
Why?
|
| Terminology as Topic | 1 | 2013 | 224 | 0.380 |
Why?
|
| Quality Improvement | 1 | 2016 | 473 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2023 | 3509 | 0.370 |
Why?
|
| Health Care Costs | 1 | 2013 | 248 | 0.370 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 261 | 0.370 |
Why?
|
| Age Factors | 5 | 2024 | 1905 | 0.360 |
Why?
|
| Sarcoidosis | 3 | 2016 | 72 | 0.350 |
Why?
|
| Transillumination | 2 | 2021 | 9 | 0.340 |
Why?
|
| Models, Statistical | 1 | 2013 | 578 | 0.330 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2022 | 12 | 0.330 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 456 | 0.330 |
Why?
|
| Systole | 3 | 2018 | 115 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1079 | 0.310 |
Why?
|
| Atrial Appendage | 2 | 2021 | 37 | 0.310 |
Why?
|
| Myocardium | 2 | 2024 | 586 | 0.300 |
Why?
|
| Heart Valve Diseases | 2 | 2024 | 118 | 0.300 |
Why?
|
| Risk Factors | 6 | 2024 | 5704 | 0.290 |
Why?
|
| Linear Models | 3 | 2018 | 427 | 0.290 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 996 | 0.290 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2024 | 89 | 0.270 |
Why?
|
| Cardiology | 3 | 2025 | 123 | 0.270 |
Why?
|
| Prosthesis Design | 2 | 2019 | 303 | 0.270 |
Why?
|
| Young Adult | 11 | 2022 | 6624 | 0.270 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 56 | 0.250 |
Why?
|
| Survival Rate | 4 | 2024 | 1927 | 0.250 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 1592 | 0.250 |
Why?
|
| Pandemics | 2 | 2021 | 812 | 0.240 |
Why?
|
| Aorta | 3 | 2021 | 291 | 0.240 |
Why?
|
| Software | 3 | 2022 | 675 | 0.230 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 3053 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 608 | 0.220 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2024 | 30 | 0.220 |
Why?
|
| Italy | 3 | 2019 | 109 | 0.220 |
Why?
|
| Amyloid | 1 | 2024 | 94 | 0.220 |
Why?
|
| Cohort Studies | 5 | 2018 | 2978 | 0.210 |
Why?
|
| Pattern Recognition, Automated | 1 | 2024 | 222 | 0.210 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2024 | 190 | 0.210 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 316 | 0.200 |
Why?
|
| Cardiomegaly, Exercise-Induced | 1 | 2022 | 1 | 0.200 |
Why?
|
| Multimodal Imaging | 3 | 2023 | 115 | 0.200 |
Why?
|
| Europe | 3 | 2021 | 328 | 0.200 |
Why?
|
| Peptide Fragments | 1 | 2024 | 465 | 0.190 |
Why?
|
| Electric Countershock | 1 | 2022 | 56 | 0.190 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 3775 | 0.190 |
Why?
|
| Organ Size | 3 | 2019 | 375 | 0.180 |
Why?
|
| Endocarditis | 1 | 2021 | 22 | 0.180 |
Why?
|
| Stress, Mechanical | 3 | 2016 | 256 | 0.180 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2022 | 72 | 0.180 |
Why?
|
| Treatment Outcome | 6 | 2022 | 8740 | 0.180 |
Why?
|
| Comorbidity | 3 | 2021 | 987 | 0.180 |
Why?
|
| Survival Analysis | 4 | 2018 | 1511 | 0.170 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 99 | 0.170 |
Why?
|
| Virtual Reality | 1 | 2020 | 29 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2025 | 601 | 0.170 |
Why?
|
| Pulmonary Artery | 2 | 2019 | 330 | 0.160 |
Why?
|
| Aminobutyrates | 1 | 2019 | 13 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2019 | 24 | 0.160 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 46 | 0.160 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 30 | 0.160 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 72 | 0.160 |
Why?
|
| Vasodilation | 1 | 2019 | 93 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2680 | 0.160 |
Why?
|
| Time Factors | 6 | 2019 | 5430 | 0.160 |
Why?
|
| Chicago | 3 | 2019 | 1466 | 0.160 |
Why?
|
| Gadolinium | 2 | 2023 | 104 | 0.160 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1902 | 0.160 |
Why?
|
| Septal Occluder Device | 1 | 2019 | 51 | 0.160 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2019 | 70 | 0.160 |
Why?
|
| Forecasting | 2 | 2018 | 311 | 0.150 |
Why?
|
| Diuretics | 1 | 2019 | 78 | 0.150 |
Why?
|
| Cicatrix | 1 | 2019 | 71 | 0.150 |
Why?
|
| Quebec | 2 | 2015 | 11 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2020 | 708 | 0.150 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1774 | 0.150 |
Why?
|
| Dilatation | 1 | 2018 | 49 | 0.140 |
Why?
|
| Tachycardia, Ventricular | 1 | 2019 | 124 | 0.140 |
Why?
|
| Reference Standards | 1 | 2018 | 144 | 0.140 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 305 | 0.140 |
Why?
|
| Feasibility Studies | 5 | 2019 | 800 | 0.140 |
Why?
|
| Device Removal | 1 | 2019 | 163 | 0.140 |
Why?
|
| Body Size | 1 | 2017 | 95 | 0.140 |
Why?
|
| ROC Curve | 4 | 2024 | 785 | 0.130 |
Why?
|
| Coronary Stenosis | 1 | 2016 | 39 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 743 | 0.130 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 64 | 0.130 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1996 | 41 | 0.130 |
Why?
|
| Adolescent | 7 | 2022 | 9504 | 0.130 |
Why?
|
| Radiation Protection | 1 | 2016 | 26 | 0.130 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2015 | 33 | 0.120 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 217 | 0.120 |
Why?
|
| Phenotype | 1 | 2022 | 2498 | 0.120 |
Why?
|
| Artificial Intelligence | 3 | 2024 | 358 | 0.120 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2015 | 68 | 0.120 |
Why?
|
| Chordae Tendineae | 1 | 2015 | 23 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2016 | 197 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 248 | 0.120 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 488 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 1996 | 704 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 267 | 0.110 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 65 | 0.110 |
Why?
|
| Heart Block | 1 | 2013 | 31 | 0.110 |
Why?
|
| Models, Economic | 1 | 2013 | 63 | 0.100 |
Why?
|
| Cost Savings | 1 | 2013 | 72 | 0.100 |
Why?
|
| Color | 1 | 2013 | 85 | 0.100 |
Why?
|
| Iatrogenic Disease | 1 | 2013 | 71 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 340 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 201 | 0.100 |
Why?
|
| Tertiary Care Centers | 1 | 2012 | 120 | 0.090 |
Why?
|
| Workflow | 2 | 2023 | 80 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 807 | 0.090 |
Why?
|
| United States | 5 | 2025 | 7348 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2012 | 214 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2017 | 806 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 490 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 1996 | 1399 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2013 | 1111 | 0.080 |
Why?
|
| Prevalence | 2 | 2024 | 1294 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2729 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2017 | 2369 | 0.070 |
Why?
|
| Elastic Modulus | 2 | 2016 | 38 | 0.070 |
Why?
|
| Electrocardiography | 2 | 2021 | 507 | 0.060 |
Why?
|
| Cause of Death | 2 | 2017 | 270 | 0.060 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 107 | 0.060 |
Why?
|
| Healthy Aging | 1 | 2024 | 13 | 0.060 |
Why?
|
| Walk Test | 1 | 2024 | 26 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2024 | 55 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2016 | 901 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 172 | 0.050 |
Why?
|
| Radiology | 2 | 2016 | 205 | 0.050 |
Why?
|
| Prealbumin | 1 | 2023 | 38 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 77 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2023 | 83 | 0.050 |
Why?
|
| Athletes | 1 | 2022 | 55 | 0.050 |
Why?
|
| Disease Progression | 2 | 2016 | 1503 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2021 | 159 | 0.040 |
Why?
|
| Abscess | 1 | 2021 | 95 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 328 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 199 | 0.040 |
Why?
|
| Valsartan | 1 | 2019 | 11 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 41 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2019 | 55 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 61 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2019 | 40 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 206 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 132 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2019 | 121 | 0.040 |
Why?
|
| Aging | 1 | 2024 | 738 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 314 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 74 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 444 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 341 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2018 | 155 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 291 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Hypertonic Solutions | 1 | 1996 | 17 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 337 | 0.030 |
Why?
|
| Culture Media | 1 | 1996 | 149 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 124 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2016 | 248 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 955 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2015 | 271 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 230 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 171 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 28003 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 112 | 0.030 |
Why?
|
| Stomach | 1 | 2015 | 111 | 0.030 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2014 | 19 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 1052 | 0.030 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2014 | 27 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 274 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 900 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 866 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 871 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2012 | 89 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 219 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1194 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1661 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 902 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 342 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2012 | 774 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2368 | 0.010 |
Why?
|
| Stroke | 1 | 2014 | 1038 | 0.010 |
Why?
|